Aditext以3600万美元的优先股交易收购Telecite Proteomics;股价下跌

2026-03-14 02:25

Aditxt (ADTX) acquired 100% of Ignite Proteomics from IMAC Holdings plus $475K in cash.
The deal consideration was 36,000 Series A-2 convertible preferred shares valued at $36M (stated value $1,000 each).
The preferred shares are convertible into common stock at $2.731 per share, subject to adjustments and a 9.99% ownership cap.
Aditxt also issued $3.19M in promissory notes (9-month maturity) with $2.875M funded at closing and 6% interest (12% upon default).
The company said the acquisition restores its stockholders’ equity above $2.5M, helping it regain compliance with Nasdaq.
ADTX shares tumble over 37%.

More on Aditx Therapeutics